Product Details
| Product Name:
BPR1J-097 |
CAS No.:
1327167-19-0 |
| Purity:
99.3% |
Supply Ability:
10g |
| Release date:
2024/11/07 |
Product Introduction
Bioactivity
| 名稱 | BPR1J-097 |
| 描述 | BPR1J-097) is a novel FLT-3 inhibitor(IC50: 11±7 nM) with promising in vivo anti-tumor activities. It also inhibits FLT-3 D835Y (IC50: 3 nM). |
| 激酶實(shí)驗(yàn) | Kinase assays: To assay Plk1 and Aurora A kinase activity, cells are lysed after 13 hrs release in the presence of SBE13 after double thymidine block, and kinases are immunoprecipitated from lysates using antibodies as described. In brief, for each immunoprecipitation 800 μg of total protein were incubated with 1.5 μg Plk1 antibody cocktail, 3 μg Plk2 antibody, 3 μg Plk3 antibody, or 5 μg Aurora A antibody, respectively, for 2 hrs at 4°C on a rotator. Immunoprecipitated protein is collected using Protein G Agarose beads. The Plk1, Plk2 and Plk3 immunoprecipitates are incubated with 1 μg casein and with 1 μCi of [γ32-P]ATP for 30 min at 37°C in kinase buffer. The Aurora A immunoprecipitates are incubated with 0.5 μl Histone and with 1 μCi of [γ32-P]ATP for 60 min at room temperature in kinase buffer. Products from the kinase assays are fractionated on 10% Bis-Tris-polyacrylamide gels, and the phosphorylated substrate is visualized by autoradiography after an exposure of 12 to 36 hrs. An equal amount of immunoprecipitates is subjected to western blot analysis to confirm equal loading of Plk1, Plk2, Plk3 or Aurora A protein in kinase reactions. Immunoprecipitated Plk1 after 13 hrs release in the presence of SBE13 is assayed after de-phosphorylation using λ protein phosphatase and compared to kinase activity of endogenous immunoprecipitated Plk1. Activity of Plk1 kinase with and wiiiuithout de-phosphorylation is compared and the ratio between de-phosphorylated and "normal" endogenous immunoprecipitated Plk1 kinase activity is calculated. |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 11 mg/mL (21.29 mM), Sonication is recommended.
|
| 關(guān)鍵字 | CD135 | Fms like tyrosine kinase 3 | BPR-1J-097 | BPR1J-097 | FLT3 | Cluster of differentiation antigen 135 | inhibit | BPR1J 097 | Inhibitor |
| 相關(guān)產(chǎn)品 | UNC2025 | Gilteritinib | Fedratinib | Nintedanib | Sunitinib | Sunitinib Malate | Sorafenib | Tandutinib | Pexidartinib | KW-2449 | Sorafenib tosylate | SGI-1776 |
| 相關(guān)庫 | 表型篩選靶點(diǎn)鑒定庫 | 經(jīng)典已知活性庫 | 酪氨酸激酶分子庫 | 激酶抑制劑庫 | 血管生成庫 | 抑制劑庫 | NO PAINS 化合物庫 | 已知活性化合物庫 | 抗癌化合物庫 | 抗癌活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:822-82-2
$30.00 / 50mg
-
-
CAS:743456-83-9
$35.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1820.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 |
United States